Moderna files fda application for the jn.1 targeting covid-19 vaccine

Manufacturing is underway and doses of moderna's spikevax 2024-2025 formula will be ready to ship as early as august, pending regulatory approval cambridge, ma / accesswire / june 7, 2024 / moderna, inc. (nasdaq:mrna) today announced that it has submitted an application to the u.s. food and drug administration (fda) for review of its spikevax 2024-2025 formula, targeting the sars-cov-2 variant jn.1. "for four years, moderna has consistently delivered vaccines that offer protection against covid-19, and work is well underway to provide a vaccine targeting jn.1," said stÉphane bancel, ceo of moderna.
MRNA Ratings Summary
MRNA Quant Ranking